Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 6, 2020
Reporting Period: Events occurring on August 6, 2020, with a press release issued August 10, 2020.
The Company executed a series of material definitive agreements and financing transactions on August 6, 2020, centered on the acquisition of wound care assets and the restructuring of its capital structure.
Key Financial Metrics and Transactions
This filing details specific transaction values rather than standard periodic financial statements (revenue, profit, cash flow). Key financial figures include:
- Asset Acquisition Cost: $24,000,000 total consideration for Celularity's UltraMIST assets.
- Private Placement Proceeds: Sale of 119,125,000 shares and warrants at $0.20 per unit.
- New Debt Issuance: $15,000,000 in secured notes (NH Expansion Credit Fund).
- Debt Repayment/Restructuring: $4,000,000 cash paid to HealthTronics; $1,210,000 LGH Note repaid; $1,000,000 Stolarski Line of Credit terminated.
- Convertible Notes Issued: $4,000,000 (Celularity), $1,372,743 (HealthTronics), and $223,511 (Stolarski).
Material Changes and Agreements
Acquisition of Celularity Assets
The Company acquired Celularity Inc.'s UltraMIST assets for $24,000,000. Consideration consisted of:
- $18,890,000 cash payment.
- $4,000,000 Seller Note (12% interest, convertible to common stock at $0.10/share if not repaid by Jan 1, 2021).
- $1,110,000 credit for a prior payment.
Concurrently, the Company secured an exclusive license for Biovance and a non-exclusive license for Interfyl for a five-year term with automatic renewal.
Capital Raising and Debt Financing
- Private Placement: Sold 119,125,000 shares and accompanying warrants (exercise price $0.25, 3-year term) to accredited investors at $0.20 per share.
- Secured Notes (NH Expansion): Issued $15,000,000 in notes maturing September 30, 2025. Interest accrues at Prime Rate (min 3%) + 9%, plus 3% paid in kind. Secured by substantially all Company assets.
- HealthTronics Restructuring: Paid off outstanding debt via $4,000,000 cash, warrant exercise (7,200,000 shares), issuance of a $1,372,743 convertible note, and issuance of 8,275,235 new shares plus warrants.
- Stolarski Restructuring: Terminated a $1,000,000 line of credit and issued a $223,511 convertible note in exchange.
Unregistered Equity Sales
The Company issued 2,250,000 shares of Common Stock to George Johnson and Kerri Johnson pursuant to the conversion of short-term promissory notes totaling $210,000.
Outlook, Risks, and Contingencies
- Liquidity Covenants: The $15 million secured note agreement includes a minimum liquidity covenant and limitations on further indebtedness, liens, and distributions.
- Dilution Risk: Significant potential dilution exists due to the issuance of 119,125,000 shares in the private placement, warrants issued to placement agents and lenders, and the conversion features of multiple notes (Celularity, HealthTronics, Stolarski) at a low conversion price of $0.10 per share.
- Registration Obligation: The Company must file a registration statement for the private placement shares within 60 days of closing.
- Financial Statements: Pro forma financial information and financial statements of the acquired business are not included in this filing but will be filed within 71 days if required.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can meet the $18,890,000 cash portion of the Celularity acquisition and the $4,000,000 cash payment to HealthTronics.
- Review the full text of the Note and Warrant Purchase and Security Agreement (Exhibit 10.5) to understand the specific "minimum liquidity covenant" and restrictions on operations.
- Assess the impact of the $0.10 conversion price on the Celularity, HealthTronics, and Stolarski notes relative to the current market price of the stock.
- Confirm the filing of the registration statement for the 119,125,000 private placement shares within the 60-day window.
- Monitor the upcoming filing of pro forma financial information to understand the combined entity's financial health post-acquisition.